Clinical trial NCT05754125: In Vivo and in Vitro Anabolic Potential of Essential Amino Acids Following Resistance Exercise
Official title: In Vivo and in Vitro Anabolic Potential of Essential Amino Acids Following Resistance Exercise
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: NA
Conditions: Interventional
Keywords: Di-leucine
Branched chain amino acids
Collagen
Amino acids
anabolism
catabolism
Lead sponsor: University of Toronto
Sponsor class: OTHER
First posted: 2023-03-03
Enrollment: 12
Sex: ALL
Minimum age (years): 18
Maximum age (years): 35
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Intervention model description: Cross over study design; Block randomized.
Primary purpose: TREATMENT

Brief summary: This study seeks to investigate the anabolic potential of a dileucine-enriched essential amino acid (EAA) formulation compared with a branched chain amino acid (BCAA) alternative and a collagen beverage on muscle protein anabolism and catabolism following a bout of resistance exercise training. To do this, investigators will employ a novel 'breath test' method developed in our laboratory as well as blood and urine sampling. The results of this study will allow us to better understand the anabolic potential of dileucine which could have implications for people engaging in regular resistance training (such as athletes) as well as people that need to preserve muscle mass (older people who are susceptible to anabolic resistance and sarcopenia, or muscle wasting).


Eligibility criteria: Inclusion Criteria:

* Trained individuals currently performing structured exercise (e.g., running, weightlifting, team-sport activity) at least 2 days per week for the previous 3 months

Exclusion Criteria:

* Inability to perform physical activity as determined by the PAR-Q
* Inability to adhere to protocol guidelines (e.g., alcohol, habitual diet)
* Regular tobacco use
* Illicit drug use (e.g., growth hormone, testosterone, etc.)
* Diagnosed medical condition under the care of a physician (e.g. type 2 diabetes)
* Inability to abstain from supplements (e.g. protein, creatine, HMB, BCAA, phosphatidic acid, etc.) at least three weeks before the trial
* Individuals on any medications known to affect protein metabolism (e.g., corticosteroids, non-steroidal anti-inflammatories, or prescription-strength acne medications)
* Participants that are amenorrheic (females only)
* On medications that may interfere with protein metabolism (e.g. anti-inflammatory drugs, hormone therapy)
* Regular tobacco use (e.g. daily use of oral or inhaled tobacco)
* Illicit drug use (e.g. growth hormone, testosterone, etc.)
* Inability to comply with the study protocol as judged by the investigators

Primary outcomes:
measure: Whole-Body Protein Synthesis
timeFrame: 6 hours
Secondary outcomes:
measure: Urinary Measures (Muscle Protein Breakdown)
timeFrame: 6 hours
measure: Murine Cell-Based Experiments (ex-vivo experiments) -hypertrophy
timeFrame: 60 minutes
measure: Murine Cell-Based Experiments (ex-vivo experiments) - Protein Synthesis
timeFrame: 60 minutes
measure: Murine Cell-Based Experiments (ex-vivo experiments) - mTORC1 Signalling
timeFrame: 60 minutes
Other outcomes:
Locations:
city: Toronto
country: Canada
facility: Goldring Centre for High Performance Sport at the University of Toronto
state: Ontario
Study officials:
References: